Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Evidence-based hyponatremia management in liver disease

Ji Young Ryu, Seon Ha Baek, Sejoong Kim

Clin Mol Hepatol. 2023;29(4):924-944. Published online June 5, 2023

DOI: https://doi.org/10.3350/cmh.2023.0090

View: 3274 Download: 239 Web of Science: 3 Crossref: 4

Special Review

Waiting for the changes after the adoption of steatotic liver disease

Eileen L. Yoon, Dae Won Jun

Clin Mol Hepatol. 2023;29(4):844-850. Published online September 6, 2023

DOI: https://doi.org/10.3350/cmh.2023.0291

View: 2155 Download: 161 Web of Science: 5 Crossref: 13

Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity

Gi-Ae Kim, Joon Ho Moon, Won Kim

Clin Mol Hepatol. 2023;29(4):831-843. Published online August 25, 2023

DOI: https://doi.org/10.3350/cmh.2023.0277

View: 3635 Download: 342 Web of Science: 8 Crossref: 17

Correspondence

Correspondence on Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”

Seul Ki Han, Soon Koo Baik, Moon Young Kim

Clin Mol Hepatol. 2023;29(3):817-819. Published online May 17, 2023

DOI: https://doi.org/10.3350/cmh.2023.0155

View: 1795 Download: 44

Letter to the Editor

Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”

Seogsong Jeong, Yohwan Lim, Su Kyoung Lee, Hyun Wook Han

Clin Mol Hepatol. 2023;29(3):810-811. Published online May 8, 2023

DOI: https://doi.org/10.3350/cmh.2023.0129

View: 1832 Download: 56 Web of Science: 1

Original Article

Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis

Yu Jun Wong, Vy H. Nguyen, Hwai-I Yang, Jie Li, Michael Huan Le, Wan-Jung Wu, Nicole Xinrong Han, Khi Yung Fong, Elizebeth Chen, Connie Wong, Fajuan Rui, Xiaoming Xu, Qi Xue, Xin Yu Hu, Wei Qiang Leow, George Boon-Bee Goh, Ramsey Cheung, Grace Wong, Vincent Wai-Sun Wong, Ming-Whei Yu, Mindie H. Nguyen

Clin Mol Hepatol. 2023;29(3):705-720. Published online May 8, 2023

DOI: https://doi.org/10.3350/cmh.2023.0004

View: 3873 Download: 215 Web of Science: 12 Crossref: 16

Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis

Min Jeong Park, Hayeon Kim, Myeong Gyu Kim, Kyungim Kim

Clin Mol Hepatol. 2023;29(3):693-704. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2022.0330

View: 3005 Download: 157 Web of Science: 4 Crossref: 4

Review

A decade of liver organoids: Advances in disease modeling

Yue Liu, Jian-Ying Sheng, Chun-Fang Yang, Junjun Ding, Yun-Shen Chan

Clin Mol Hepatol. 2023;29(3):643-669. Published online March 6, 2023

DOI: https://doi.org/10.3350/cmh.2022.0428

View: 8510 Download: 268 Crossref: 1

Editorial

The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review

Young-Joo Jin

Clin Mol Hepatol. 2023;29(2):414-416. Published online February 28, 2023

DOI: https://doi.org/10.3350/cmh.2023.0055

View: 4099 Download: 63

How to optimize the outcome of liver transplantation for non-alcoholic fatty liver disease

Byeong Geun Song, Dong Hyun Sinn

Clin Mol Hepatol. 2023;29(2):411-413. Published online March 6, 2023

DOI: https://doi.org/10.3350/cmh.2023.0058

View: 2095 Download: 46 Web of Science: 1 Crossref: 1

The effect of moderate alcohol consumption on nonalcoholic fatty liver disease

Ji-Won Park, Ki Tae Suk

Clin Mol Hepatol. 2023;29(2):408-410. Published online March 16, 2023

DOI: https://doi.org/10.3350/cmh.2023.0085

View: 2342 Download: 67 Web of Science: 2 Crossref: 2

Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?

Margaret LP Teng, Darren Jun Hao Tan, Cheng Han Ng, Daniel Q. Huang

Clin Mol Hepatol. 2023;29(2):404-407. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0069

View: 2641 Download: 73 Web of Science: 2 Crossref: 2

Implications of comorbidities in nonalcoholic fatty liver disease

Sherlot Juan Song, Vincent Wai-Sun Wong

Clin Mol Hepatol. 2023;29(2):384-389. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0066

View: 2892 Download: 74 Web of Science: 1 Crossref: 1

Non-obese or lean nonalcoholic fatty liver disease matters, but is it preventable or inevitable in light of its risk factors?

Heejoon Jang, Won Kim

Clin Mol Hepatol. 2023;29(2):381-383. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0088

View: 2634 Download: 76 Web of Science: 2 Crossref: 3

Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?

Ho Soo Chun, Minjong Lee

Clin Mol Hepatol. 2023;29(2):377-380. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0061

View: 2385 Download: 94 Web of Science: 2 Crossref: 1

The growing burden of non-alcoholic fatty liver disease on mortality

Ju-Yeon Cho, Won Sohn

Clin Mol Hepatol. 2023;29(2):374-376. Published online March 6, 2023

DOI: https://doi.org/10.3350/cmh.2023.0084

View: 2247 Download: 64

Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology

Eileen Laurel Yoon, Dae Won Jun

Clin Mol Hepatol. 2023;29(2):371-373. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0086

View: 2645 Download: 113 Web of Science: 3 Crossref: 3

Review

Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives

Shang-Chin Huang, Chun-Jen Liu

Clin Mol Hepatol. 2023;29(2):320-331. Published online February 1, 2023

DOI: https://doi.org/10.3350/cmh.2022.0422

View: 5025 Download: 339 Web of Science: 10 Crossref: 13

Correspondence

Correspondence on Editorial regarding “Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations”

Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn

Clin Mol Hepatol. 2023;29(1):185-187. Published online November 10, 2022

DOI: https://doi.org/10.3350/cmh.2022.0375

View: 2545 Download: 37

Letter to the Editor

Correspondence on Letter regarding “COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis”

Ka Shing Cheung, Chiu Hang Mok, Wai Kay Seto, Man Fung Yuen

Clin Mol Hepatol. 2023;29(1):176-178. Published online November 10, 2022

DOI: https://doi.org/10.3350/cmh.2022.0377

View: 2580 Download: 49

Correspondence on Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”

Seung Min Lee, Dae Won Jun

Clin Mol Hepatol. 2023;29(1):171-172. Published online November 10, 2022

DOI: https://doi.org/10.3350/cmh.2022.0381

View: 2641 Download: 53

Letter regarding “The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults”

Hye Won Lee

Clin Mol Hepatol. 2023;29(1):169-170. Published online November 10, 2022

DOI: https://doi.org/10.3350/cmh.2022.0384

View: 2834 Download: 45 Web of Science: 1 Crossref: 1

Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”

Yuanbin Liu, Mingkai Chen

Clin Mol Hepatol. 2023;29(1):163-164. Published online October 27, 2022

DOI: https://doi.org/10.3350/cmh.2022.0326

View: 2980 Download: 59 Web of Science: 1 Crossref: 1

Review

Development and prognosis of hepatocellular carcinoma in patients with diabetes

Takuma Nakatsuka, Ryosuke Tateishi

Clin Mol Hepatol. 2023;29(1):51-64. Published online July 29, 2022

DOI: https://doi.org/10.3350/cmh.2022.0095

View: 5030 Download: 231 Web of Science: 11 Crossref: 12

Wnt signaling in liver regeneration, disease, and cancer

Gengyi Zou, Jae-Il Park

Clin Mol Hepatol. 2023;29(1):33-50. Published online July 4, 2022

DOI: https://doi.org/10.3350/cmh.2022.0058

View: 5772 Download: 243 Web of Science: 9 Crossref: 10

Subclinical versus advanced forms of alcohol-related liver disease: Need for early detection

Concepción Gómez-Medina, Luma Melo, David Martí-Aguado, Ramón Bataller

Clin Mol Hepatol. 2023;29(1):1-15. Published online April 15, 2022

DOI: https://doi.org/10.3350/cmh.2022.0017

View: 9168 Download: 172 Web of Science: 3 Crossref: 3

Snapshot

Personalized medicine in nonalcoholic fatty liver disease

Carlos J. Pirola, Silvia Sookoian

Clin Mol Hepatol. 2022;28(4):935-938. Published online June 24, 2022

DOI: https://doi.org/10.3350/cmh.2022.0175

View: 3767 Download: 137 Web of Science: 4 Crossref: 4

Letter to the Editor

Non-alcoholic fatty liver disease and risk of dementia: Unmet need for a pooled analysis of cohort studies

Seogsong Jeong, Won Kim, Sang Min Park

Clin Mol Hepatol. 2022;28(4):933-934. Published online September 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0267

View: 2714 Download: 63

Non-alcoholic fatty liver disease and the risk of dementia: A meta-analysis of cohort studies

Li-Yu Lu, Min-You Wu, Yung-Shuo Kao, Cheng-Hsien Hung

Clin Mol Hepatol. 2022;28(4):931-932. Published online September 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0259

View: 2747 Download: 96 Web of Science: 7 Crossref: 6

Original Article

COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis

Ka Shing Cheung, Chiu Hang Mok, Xianhua Mao, Ruiqi Zhang, Ivan FN Hung, Wai Kay Seto, Man Fung Yuen

Clin Mol Hepatol. 2022;28(4):890-911. Published online June 3, 2022

DOI: https://doi.org/10.3350/cmh.2022.0087

View: 5133 Download: 182 Web of Science: 26 Crossref: 31

1 | 2 | 3 | 4 | 5 | 6 | 7 |

Viewed By 5906	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5266	MAFLD: How is it different from NAFLD?
Viewed By 4977	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4068	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4047	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Cited By 137	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 104	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 82	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 71	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 66	MAFLD: How is it different from NAFLD?

Search